STTK · Shattuck Labs, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.00M | $5.72M | $1.66M | $652.0K | $30.02M | $9.93M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $35.27M | $67.21M | $74.31M | $82.90M | $56.56M | $37.48M |
| SG&A | $17.23M | $19.08M | $19.30M | $21.08M | $18.72M | $9.38M |
| Total Operating Expenses | $52.51M | $86.29M | $93.61M | $103.98M | $75.29M | $46.87M |
| D&A | $3.70M | $3.80M | $4.00M | $3.10M | $1.40M | $600.0K |
| Operating Income | ($51.51M) | ($80.57M) | ($91.96M) | ($103.33M) | ($45.27M) | ($36.93M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($48.81M) | ($75.41M) | ($87.30M) | ($101.94M) | ($44.97M) | ($36.60M) |
| EPS - Basic | ($0.70) | ($1.49) | ($2.05) | ($2.41) | ($2.36) | - |
| EPS - Diluted | ($0.70) | ($1.49) | ($2.05) | ($2.41) | ($2.36) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.19M | $57.39M | $125.63M | $47.38M | $92.27M | $157.90M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.10M | $2.42M | $1.59M | $7.17M | $10.01M | $1.75M |
| Current Assets | $82.47M | $79.22M | $143.22M | $184.58M | $288.27M | $345.64M |
| Total Assets | $91.03M | $91.05M | $159.56M | $205.32M | $298.58M | $348.99M |
| Current Liabilities | $7.05M | $8.92M | $11.45M | $24.96M | $24.59M | $16.83M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $8.64M | $11.42M | $14.86M | $29.17M | $26.80M | $39.13M |
| Stockholders' Equity | $82.39M | $79.63M | $144.71M | $176.16M | $271.79M | $309.86M |
| Retained Earnings | ($430.53M) | ($381.72M) | ($306.31M) | ($219.01M) | ($117.07M) | ($72.09M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($39.88M) | ($60.52M) | ($81.23M) | ($94.50M) | ($57.12M) | ($33.66M) |
| Investing Cash Flow | ($7.89M) | ($8.51M) | $110.86M | $49.44M | ($10.44M) | ($146.32M) |
| Financing Cash Flow | $44.57M | $787.0K | $48.62M | $171.0K | $1.93M | $330.87M |
| CapEx | $71.0K | $59.0K | $407.0K | $11.61M | $7.93M | $727.0K |
| Free Cash Flow | ($39.95M) | ($60.57M) | ($81.64M) | ($106.11M) | ($65.04M) | ($34.39M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -5150.8% | -1408.3% | -5549.6% | -15848.0% | -150.8% | -371.8% |
| EBITDA margin | -4780.8% | -1341.8% | -5308.2% | -15372.5% | -146.1% | -365.7% |
| Net margin | -4880.9% | -1318.1% | -5268.4% | -15635.7% | -149.8% | -368.5% |
| Free cash flow margin | -3995.3% | -1058.8% | -4926.7% | -16274.8% | -216.7% | -346.1% |
| FCF / Net income | 0.82 | 0.80 | 0.94 | 1.04 | 1.45 | 0.94 |
| R&D / Revenue | 3527.3% | 1174.8% | 4484.6% | 12714.6% | 188.4% | 377.3% |
| SG&A / Revenue | 1723.5% | 333.5% | 1165.0% | 3233.4% | 62.4% | 94.4% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -53.6% | -82.8% | -54.7% | -49.7% | -15.1% | -10.5% |
| Return on equity | -59.2% | -94.7% | -60.3% | -57.9% | -16.5% | -11.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 11.70 | 8.88 | 12.51 | 7.39 | 11.72 | 20.53 |
| Quick ratio | 11.70 | 8.88 | 12.51 | 7.39 | 11.72 | 20.53 |
| Cash ratio | 7.68 | 6.44 | 10.97 | 1.90 | 3.75 | 9.38 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.10 | 1.14 | 1.10 | 1.17 | 1.10 | 1.13 |
| Liabilities / Assets | 0.09 | 0.13 | 0.09 | 0.14 | 0.09 | 0.11 |
| Efficiency | ||||||
| Asset turnover | 0.01 | 0.06 | 0.01 | 0.00 | 0.10 | 0.03 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.1x | 0.8x | 2.1x | 0.6x | 0.5x | - |
| P / S | 254.0x | 10.7x | 183.3x | 149.5x | 4.4x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -82.5% | 245.3% | 154.1% | -97.8% | 202.2% | - |
| Revenue CAGR (3y) | 15.3% | -42.5% | -45.0% | - | - | - |
| Revenue CAGR (5y) | -36.8% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 36.1% | 12.4% | 11.0% | -128.3% | -22.6% | - |
| Net income growth (YoY) | 35.3% | 13.6% | 14.4% | -126.7% | -22.9% | - |
| EPS growth (YoY) | 53.0% | 27.3% | 14.9% | -2.1% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 34.0% | 25.8% | 23.1% | -63.1% | -89.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 3.5% | -45.0% | -17.9% | -35.2% | -12.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.00M totalReportable Segment$1.00M · 100.0%
Product / service
$1.00M totalLicense$1.00M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-1.15
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Shattuck Labs against the 5 most active filers in the same SIC group.